Compare Oxford Lane Capital Corp (OXLC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs TG Therapeutics Inc — how do they compare? Oxford Lane Capital Corp trades at $8.84 (market cap $861.22M), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: TG Therapeutics Inc is far larger — about 9.6× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 27.21% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| OXLC | TGTX | |
|---|---|---|
Market Cap | $861.22M | $8.26B |
Sector | Financials | Health |
52-Week High | $19.90 | $59.06 |
52-Week Low | $8.15 | $26.39 |
Dividend Yield | 27.21% | — |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.87, up 1.14% today, but faces a bearish technical outlook with significant selling pressure. The company reported a net income of $48.46 million for 2025, but recent quarterly earnings have consistently missed expectations, including a substantial miss in Q1 2026. Despite a high dividend yield, financial performance shows strain with negative ROE and ROA, while cash flow is heavily dependent on financing activities.
The outlook is cautious due to deteriorating fundamentals, negative profitability metrics, and bearish analyst sentiment. The primary opportunity lies in the high dividend yield, but risks include unsustainable distributions, declining net asset value, and potential for further earnings volatility. Investor caution is warranted given the conflicting signals between dividend income and underlying financial health.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
